•  
  •  
 

The Thai Journal of Pharmaceutical Sciences

Abstract

Coronary artery disease (CAD) remains a major contributor to global morbidity and mortality, necessitating robust secondary prevention strategies. Antiplatelet therapy, particularly aspirin, has long been the cornerstone in CAD management, effectively reducing thrombotic events postacute coronary syndrome and in patients with chronic coronary syndrome. However, aspirin’s association with gastrointestinal (GI) bleeding and the emergence of alternative agents like clopidogrel have debate over the optimal monotherapy for CAD patients. Clopidogrel, a P2Y12 receptor antagonist, is increasingly considered a viable alternative, especially for patients at high risk of GI complications or aspirin intolerance. Recent clinical trials and updated guidelines have emphasized the need to reassess the roles of clopidogrel and aspirin, particularly in longterm secondary prevention. This review critically evaluates the comparative efficacy and safety of clopidogrel versus aspirin monotherapy, exploring genetic factors, bleeding risks, and the evolving role of personalized medicine. By analyzing current evidence, we provide insights into whether clopidogrel should be favored over aspirin in select populations, while highlighting the implications for future clinical practice and guideline development.

DOI

10.56808/3027-7922.2968

Download

Share

COinS